Biolinq Raises $58m

Written by

Jennifer Kastner

SAN DIEGO- Wearable tech startup Biolinq landed $58 million in funding to fuel the development of its ultra-tiny skin patch that uses electrochemical sensors to measure glucose levels in patients with metabolic syndromes like diabetes. The company's burgeoning success has the potential to shake up a glucose monitoring market that's dominated by heave hitters like Dexcom and Abbott. Read more at: https://www.sdbj.com/life-sciences/medical-devices/biolinq-raises-58m/

‍

Other news

Mass Device

June 2, 2024

Biolinq raises $58M to support intradermal glucose sensor

Biolinq announced today that it completed $58 million financing to support the progression of its proprietary intradermal glucose sensor. Alpha Wave Ventures led the funding round. Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures also participated.

Biolinq: Less pain, $58m gain for tiny glucose sensor

In a sweet indication of an improving capital market for med-tech companies, Biolinq Inc. landed $58 million in bridge financing to support completion of the U.S. pivotal trial of its intradermal glucose sensor and submission to the U.S. FDA.

Written by

Anette Boyle

Medical Device Network

June 2, 2024

Biolinq raises $58m for glucose microsensor pivotal trial

Biolinq is eying an FDA application this year, according to CEO Richard Yang. “The pivotal study started in March 2024 and we plan to file for US Food and Drug Administration (FDA) clearance this year.” said Yang.

Written by

Robert Barrie